news in brief
Xellia starts work on Copenhagen sterile drug plant
Xellia Pharmaceutical ApS has started constructing a sterile manufacturing building at its plant in Copenhagen, Denmark.
The building – which cost $25m (€21m) – will increase production capacity for both active pharmaceutical ingredients (APIs) and finished dose anti-infective pharmaceuticals like vancomycin and colistimethate sodium.
In August, Xellia completed the expansion of its API and drug product testing facility in Budapest, Hungary.
The firm is also expanding its US sterile injectables with a production facility in Cleveland, Ohio, which is scheduled to open next year. The facility will complement an existing plant in Raleigh, North Carolina.
